0001127602-21-000541.txt : 20210105 0001127602-21-000541.hdr.sgml : 20210105 20210105162420 ACCESSION NUMBER: 0001127602-21-000541 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210104 FILED AS OF DATE: 20210105 DATE AS OF CHANGE: 20210105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zaks Tal Zvi CENTRAL INDEX KEY: 0001690927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 21505915 MAIL ADDRESS: STREET 1: 122 BELLEVUE STREET CITY: NEWTON STATE: MA ZIP: 02458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2021-01-04 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2021-01-04 4 M 0 5000 12.21 A 5000 D Common Stock 2021-01-04 4 S 0 100 103.51 D 4900 D Common Stock 2021-01-04 4 S 0 600 105.07 D 4300 D Common Stock 2021-01-04 4 S 0 445 106.52 D 3855 D Common Stock 2021-01-04 4 S 0 400 108.02 D 3455 D Common Stock 2021-01-04 4 S 0 1802 110.09 D 1653 D Common Stock 2021-01-04 4 S 0 1253 111.14 D 400 D Common Stock 2021-01-04 4 S 0 300 112.29 D 100 D Common Stock 2021-01-04 4 S 0 100 112.96 D 0 D Stock Option (Right to Buy) 12.21 2021-01-04 4 M 0 5000 0 D 2027-10-03 Common Stock 5000 189952 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.78 to $105.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.90 to $106.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.74 to $108.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.69 to $110.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.73 to $111.60 Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.74 to $112.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). /s/ Lori Henderson, as Attorney-in-Fact 2021-01-05